Pancreatic ductal adenocarcinoma: biological hallmarks, current status, and future perspectives of combined modality treatment approaches
M Orth, P Metzger, S Gerum, J Mayerle, G Schneider… - Radiation …, 2019 - Springer
Pancreatic ductal adenocarcinoma (PDAC) is a highly devastating disease with poor
prognosis and rising incidence. Late detection and a particularly aggressive biology are the …
prognosis and rising incidence. Late detection and a particularly aggressive biology are the …
A systematic review of the burden of pancreatic cancer in Europe: real-world impact on survival, quality of life and costs
Purpose The purpose of this study was to assess the overall burden of pancreatic cancer in
Europe, with a focus on survival time in a real-world setting, and the overall healthy life lost …
Europe, with a focus on survival time in a real-world setting, and the overall healthy life lost …
Irinotecan delivery by lipid-coated mesoporous silica nanoparticles shows improved efficacy and safety over liposomes for pancreatic cancer
Urgent intervention is required to improve the 5 year survival rate of pancreatic ductal
adenocarcinoma (PDAC). While the four-drug regimen, FOLFIRINOX (comprising irinotecan …
adenocarcinoma (PDAC). While the four-drug regimen, FOLFIRINOX (comprising irinotecan …
Tumor–stroma IL1β-IRAK4 feedforward circuitry drives tumor fibrosis, chemoresistance, and poor prognosis in pancreatic cancer
D Zhang, L Li, H Jiang, Q Li, A Wang-Gillam, J Yu… - Cancer research, 2018 - AACR
Targeting the desmoplastic stroma of pancreatic ductal adenocarcinoma (PDAC) holds
promise to augment the effect of chemotherapy, but success in the clinic has thus far been …
promise to augment the effect of chemotherapy, but success in the clinic has thus far been …
[HTML][HTML] CCR5/CCL5 axis interaction promotes migratory and invasiveness of pancreatic cancer cells
Pancreatic cancer (PC) is one of the deadliest cancers and remains a major challenge due
to its invasive and metastatic nature. Increased levels of CCR5 and CCL5 have established …
to its invasive and metastatic nature. Increased levels of CCR5 and CCL5 have established …
The multiple roles of exosomes in metastasis
UH Weidle, F Birzele, G Kollmorgen… - Cancer Genomics & …, 2017 - cgp.iiarjournals.org
Exosomes are important contributors to cell–cell communication and their role as diagnostic
markers for cancer and the pathogenesis for cancer is under intensive investigation. Here …
markers for cancer and the pathogenesis for cancer is under intensive investigation. Here …
[HTML][HTML] Gemcitabine combined with the monoclonal antibody nimotuzumab is an active first-line regimen inKRAS wildtype patients with locally advanced or metastatic …
Background This randomized study was designed to investigate the superiority of
gemcitabine (gem) plus nimotuzumab (nimo), an anti-epidermal growth factor receptor …
gemcitabine (gem) plus nimotuzumab (nimo), an anti-epidermal growth factor receptor …
TGF-β in pancreatic cancer initiation and progression: two sides of the same coin
W Shen, G Tao, Y Zhang, B Cai, J Sun, Z Tian - Cell & bioscience, 2017 - Springer
Pancreatic cancer is highly lethal malignant tumor with characterised rapid progression,
invasiveness and resistance to radiochemotherapy. Transforming growth factor-β (TGF-β) …
invasiveness and resistance to radiochemotherapy. Transforming growth factor-β (TGF-β) …
An overview of genetic mutations and epigenetic signatures in the course of pancreatic cancer progression
Pancreatic cancer (PC) is assumed to be an intimidating and deadly malignancy due to
being the leading cause of cancer-led mortality, predominantly affecting males of older age …
being the leading cause of cancer-led mortality, predominantly affecting males of older age …
CAR T‐cell therapy for pancreatic cancer
CJ DeSelm, ZE Tano, AM Varghese… - Journal of surgical …, 2017 - Wiley Online Library
Chimeric antigen receptor (CAR) T‐cell therapy utilizes genetic engineering to redirect a
patient's own T cells to target cancer cells. The remarkable results in hematological …
patient's own T cells to target cancer cells. The remarkable results in hematological …